Evidence map›Paper›PMID 41853570›Full record

ArticleOphthalmology science2026

OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Mai Alhelaly, Ceren Soylu, Deniz Oncel, Giulia Corradetti, Keren Chen, Nicholas J Jackson, Sivakumar R Rathinam, John A Gonzales, Radhika Thundikandy, Anuradha Vadakke Kanakath and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mai AlhelalyDepartment of Ophthalmology, Doheny Eye Institute, Pasadena, California.
Ceren SoyluDepartment of Ophthalmology, Doheny Eye Institute, Pasadena, California.
Deniz OncelDepartment of Ophthalmology, Doheny Eye Institute, Pasadena, California.
Giulia CorradettiDepartment of Ophthalmology, Doheny Eye Institute, Pasadena, California.
Keren ChenDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California.
Nicholas J JacksonDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California.
Sivakumar R RathinamUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
John A GonzalesF.I Proctor Foundation, University of California, San Francisco, San Francisco, California.
Radhika ThundikandyUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Anuradha Vadakke KanakathUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
S Bala MuruganUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
Rajesh VedhanayakiUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Lyndell L LimCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Eric B SuhlerCasey Eye Institute, Oregon Health Science University, Portland, Oregon.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Thuy DoanF.I Proctor Foundation, University of California, San Francisco, San Francisco, California.
Srinivas R SaddaDepartment of Ophthalmology, Doheny Eye Institute, Pasadena, California.
Brian MadowIra G. Ross Eye Institute, Department of Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo/State University of New York (SUNY), Buffalo, New York.
Alison B CoyneF.I Proctor Foundation, University of California, San Francisco, San Francisco, California.
Nisha R AcharyaF.I Proctor Foundation, University of California, San Francisco, San Francisco, California.
Edmund TsuiDepartment of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Funding

Objective quantification of vitreous inflammation using optical coherence tomographyR21EY034543 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSUI, EDMUND · 2023 to 2024
$447k
NEI NIH HHS R21 EY034543
6 · The paper itself

Abstract

Purpose: To evaluate OCT vitreous signal intensity (OCT-VI) as a biomarker of vitreous haze (VH) in a longitudinal, prospective, and standardized manner in the First-Line Antimetabolites as Steroid-Sparing Treatment (FAST) Uveitis Trial. Design: Secondary analysis of a block-randomized, observer-masked, multicenter clinical trial. Subjects: Two hundred sixty-seven eyes from 147 patients with uveitis enrolled in the FAST Trial were evaluated in this analysis at baseline (BL), month 6 (M6), and month 12 (M12). Methods: For each patient, Heidelberg Spectralis OCT volume scans (Heidelberg Engineering) were imported into the Doheny Reading Center 3D-OCTOR software and underwent a semi-automated segmentation. For each OCT volume, 5 B-scans were used to calculate the OCT-VI as a ratio of the vitreous space to the entire image. Main Outcome Measures: OCT vitreous signal intensity at BL, M6, and M12 visits and the association with the National Eye Institute VH scale, anterior chamber (AC) cell grade, posterior synechiae (PS), lens status, visual acuity (VA), and central macular thickness (CMT). Results: At BL, the median relative vitreous intensity was 0.43 (interquartile range, [0.33-0.54]) and reduced to 0.39 (0.27-0.53) at M6 and 0.39 (0.26-0.54) at M12. A mixed-effects linear regression model showed that OCT-VI and VH clinical grades were statistically significantly correlated ( Conclusions: In the FAST Uveitis Trial, OCT-VI was significantly correlated with the VH clinical grades and demonstrated significant longitudinal changes. OCT vitreous signal intensity may serve as a potential objective biomarker of VH. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

FASTOCT-based vitreous signal intensityStandardization of uveitis nomenclatureUveitisVitreous haze

Identifiers

PMID41853570
PMCPMC12995472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.